Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
November 07 2023 - 1:30AM
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:
DE0005664809; NASDAQ: EVO) and Dewpoint Therapeutics today
announced a strategic R&D collaboration to advance Dewpoint’s
leading oncology pipeline programs of condensate modifying
therapeutics (“c-mods”) to Investigational New Drug Applications
(“INDs”) using Evotec’s industry-leading fully integrated
data-driven platform (“INDiGO”).
The partnership brings together Dewpoint’s advanced oncology
pipeline programs discovered using its groundbreaking condensate
biology and AI technology platform for identifying modulators of
biomolecular condensates with Evotec’s leading capabilities to
de-risk and accelerate pre-clinical development candidates (“PDCs”)
to first-in-human (“FIH”) clinical studies.
Under the collaboration, Evotec will facilitate the rapid
development of Dewpoint’s oncology assets using Evotec’s fully
integrated clinical-enabling INDiGO platform to de-risk and
accelerate the path to clinical testing. The partnership also
enables Dewpoint to maximize capital efficiency while reducing
risk. The agreement is based on a risk-sharing arrangement followed
by milestone and royalty payments to Evotec based on the success of
the overall programs.
Dr. Matthias Evers, Chief Business Officer of Evotec, commented,
“We are excited to enter this strategic development partnership
with Dewpoint. Their innovative approach is based on a holistic
understanding, which can significantly expand the target space
across indications. By combining our complementary expertise,
Evotec’s development platform will serve as the capital-efficient
IND engine for this highly collaborative partnership. We look
forward to working closely together with their team to make
Dewpoint’s groundbreaking innovations available to patients.”
“Dewpoint’s strategic partnership with Evotec leverages the
world-class speed of their development platform to accelerate our
oncology assets into the clinic. Evotec’s integrated
state-of-the-art operational technologies have been proven to
deliver high quality INDs across the industry. A strategic
relationship of this nature significantly enhances our development
capabilities which can be transformative for a company at our stage
of development, and we are delighted to have been able to forge
this partnership with a leader like Evotec,” commented Ameet
Nathwani, M.D., CEO at Dewpoint.
ABOUT CONDENSATES
Condensates are membraneless organelles that form dynamically
throughout the cell via a process called phase separation. These
subcellular compartments organize and concentrate molecules within
cells to enable certain key biochemical processes. The
dysregulation of biomolecular condensates has been observed in many
diseases, including cancer, diabetes and neurological disorders.
Condensate-modifying drugs (c-mods) potentially provide novel
therapeutic options for complex diseases and historically
undruggable targets.
ABOUT DEWPOINT THERAPEUTICS
Dewpoint is the first company to apply the emerging
understanding of biomolecular condensates to drug discovery for the
vast range of conditions that are regulated by condensates or arise
from the dysfunction of condensates. Dewpoint currently has
programs across an ambitious pipeline spanning oncology,
neurodegenerative, cardiopulmonary and metabolic disease
indications, and collaborations with leading global academic and
pharmaceutical partners, including Bayer and Novo Nordisk. Dewpoint
scientists work in Boston, Dresden and Frankfurt to translate
condensate biology into medicine for diseases previously considered
untreatable. Learn more at Dewpointx.com and follow us on X
and LinkedIn.
Dewpoint Therapeutics Contacts
Mediamedia@dewpointx.com
InvestorsMichael Fenn, Ph.D.Head of External
Innovationmfenn@dewpointx.com
ABOUT EVOTEC SEEvotec is a life science company
with a unique business model that delivers on its mission to
discover and develop highly effective therapeutics and make them
available to the patients. The Company’s multimodality platform
comprises a unique combination of innovative technologies, data and
science for the discovery, development, and production of
first-in-class and best-in-class pharmaceutical products. Evotec
leverages this “Data-driven R&D Autobahn to Cures” for
proprietary projects and within a network of partners including all
Top 20 Pharma and over 800 biotechnology companies, academic
institutions, as well as other healthcare stakeholders. Evotec has
strategic activities in a broad range of currently underserved
therapeutic areas, including e.g. neurology, oncology, as well as
metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for
innovative therapeutics and has to-date established a portfolio of
more than 200 proprietary and co-owned R&D projects from early
discovery to clinical development. Evotec operates globally with
more than 5,000 highly qualified people. The Company’s 17 sites
offer highly synergistic technologies and services and operate as
complementary clusters of excellence. For additional information
please go to www.evotec.com and follow us on X/Twitter @Evotec and
LinkedIn.
Media Contact Evotec SE:Gabriele Hansen, SVP
Head of Global Corporate
CommunicationsGabriele.Hansen@evotec.com
Hinnerk RohwedderDirector of Global Corporate
CommunicationsHinnerk.Rohwedder@evotec.com
IR Contact Evotec SE:Volker BraunSVP Head of
Global Investor Relations & ESGVolker.Braun@evotec.com
FORWARD-LOOKING STATEMENTS This announcement
contains forward-looking statements concerning future events,
including the proposed offering and listing of Evotec’s securities.
Words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,”
“target,” “would” and variations of such words and similar
expressions are intended to identify forward-looking statements.
Such statements include comments regarding Evotec’s expectations
for revenues, Group EBITDA and unpartnered R&D expenses. These
forward-looking statements are based on the information available
to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be
given that such expectations will prove to have been correct. These
statements involve known and unknown risks and are based upon a
number of assumptions and estimates, which are inherently subject
to significant uncertainties and contingencies, many of which are
beyond the control of Evotec. Evotec expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Evotec’s expectations with respect thereto or
any change in events, conditions or circumstances on which any
statement is based.
Evotec (NASDAQ:EVO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Evotec (NASDAQ:EVO)
Historical Stock Chart
From Aug 2023 to Aug 2024